Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?

Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?

Purpose: Lutetium labelled prostate-specific membrane antigen radioligand therapy (Lu-PSMA RLT) has shown pleasing early results in management of high-volume metastatic castration resistant prostate cancer (mCRPC), but its role in the early treatment of men with only lymph node metastasis (LNM) is u...

Full description

Saved in:
Bibliographic Details
Main Authors: William John Yaxley, Rhiannon McBean, David Wong, David Grimes, Paul Vasey, Mark Frydenberg, John William Yaxley
Format: article
Language:EN
Published: Korean Urological Association 2021
Subjects:
lutetium-177
lymphatic metastasis
prostate cancer
psma-617
Diseases of the genitourinary system. Urology
RC870-923
Online Access:https://doaj.org/article/f09385922af24e11a3b719c3f5dde7df
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items